Back to news

Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer

Globe Newswire•18/11/2026•07:30 ET
0

Key Highlights

  • ➤Atebimetinib showed anti-tumor activity across all nine ATC cell lines evaluated
  • ➤Atebimetinib plus chemotherapy demonstrated superior tumor control versus chemotherapy alone
  • ➤Combination outperformed dabrafenib plus trametinib in a BRAF V600E-mutant ATC model
  • ➤Immuneering plans a Phase 2 trial in second-line ATC patients
  • ➤MAPKeeper 301 Phase 3 pancreatic cancer trial is enrolling ahead of schedule

Expert Statements

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“We are very excited to expand the development of atebimetinib to a third tumor type, for patients with anaplastic thyroid cancer.”

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“In first-line pancreatic cancer patients, we reported compelling data at ASCO for atebimetinib+chemo, including long survival and an excellent tolerability profile in an all-comers population, and are excited to share another update on that trial in 1H 2027.”

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“Enthusiasm is high for our Phase 3 MAPKeeper 301 trial of atebimetinib+chemo in first line pancreatic cancer patients, which is enrolling ahead of schedule, and we are preparing to dose the first patient in our Phase 2 study of atebimetinib+anti-PD-1 in first-line RAS mutant lung cancer by the end of the year.”

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“This incredible momentum gives us the opportunity to serve more patients, and the preclinical data we reported makes it clear that running a Phase 2 study of atebimetinib+chemotherapy in anaplastic thyroid cancer is an important next step for atebimetinib.”

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“We observed activity across a broad range of ATC models, including those with different underlying genetic drivers, and importantly, we saw that adding atebimetinib to chemotherapy produced substantially greater tumor control than either chemotherapy or established targeted therapy alone in our preclinical model, including following progression on targeted therapy.”

Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering Corporation

“These results reinforce our confidence in the scientific rationale for the Phase 2 ATC program we announced last week and underscore the potential of atebimetinib to help a broad and expanding set of cancer patients.”

- Atebimetinib has already reported compelling Phase 2 clinical data in first-line pancreatic cancer, is currently being evaluated in a Phase 3 trial in first-line pancreatic cancer, and will soon begin a Phase 2 trial in first-line RAS-mutant lung cancer -

- Atebimetinib demonstrated anti-tumor activity across all nine anaplastic thyroid cancer (ATC) cell lines evaluated, including BRAF V600E-mutant, RAS-mutant and MAPK-unaltered, in data presented at the 2026 EORTC-NCI-AACR Symposium -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in